Amyloid pathology reduces ELP3 expression and tRNA modifications leading to impaired proteostasis.

Marisa Pereira, Diana R Ribeiro, Maximilian Berg, Andy P Tsai, Chuanpeng Dong, Kwangsik Nho, Stefanie Kaiser, Miguel Moutinho, Ana R Soares

Biochimica et biophysica acta. Molecular basis of disease 2024 Jan

filter terms:

Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by accumulation of β-amyloid aggregates and loss of proteostasis. Transfer RNA (tRNA) modifications play a crucial role in maintaining proteostasis, but their impact in AD remains unclear. Here, we report that expression of the tRNA modifying enzyme ELP3 is reduced in the brain of AD patients and amyloid mouse models and negatively correlates with amyloid plaque mean density. We further show that SH-SY5Y neuronal cells carrying the amyloidogenic Swedish familial AD mutation (SH-SWE) display reduced ELP3 levels, tRNA hypomodifications and proteostasis impairments when compared to cells not carrying the mutation (SH-WT). Additionally, exposing SH-WT cells to the secretome of SH-SWE cells led to reduced ELP3 expression, wobble uridine tRNA hypomodification, and increased protein aggregation. Importantly, correcting tRNA deficits due to ELP3 reduction reverted proteostasis impairments. These findings suggest that amyloid pathology dysregulates proteostasis by reducing ELP3 expression and tRNA modification levels, and that targeting tRNA modifications may be a potential therapeutic avenue to restore neuronal proteostasis in AD and preserve neuronal function. Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Citation

Marisa Pereira, Diana R Ribeiro, Maximilian Berg, Andy P Tsai, Chuanpeng Dong, Kwangsik Nho, Stefanie Kaiser, Miguel Moutinho, Ana R Soares. Amyloid pathology reduces ELP3 expression and tRNA modifications leading to impaired proteostasis. Biochimica et biophysica acta. Molecular basis of disease. 2024 Jan;1870(1):166857